ADAMTS-14 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-14 (UniProt Q8WXS8), expressed in HEK293 cells. Procollagen type I N-proteinase and LOX-cleaving metalloprotease; used in activity assays, inhibitor screens, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-ADAMTS14

In stock

SKU
REC-ADAMTS14
$498.00

Target Overview

ADAMTS-14 (UniProt Q8WXS8; gene ADAMTS14) is a secreted, extracellular matrix-localised zinc metalloproteinase belonging to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. The full-length human sequence spans 1,223 amino acids and encodes a domain architecture characteristic of the family: a signal peptide, prodomain, catalytic metalloprotease domain, disintegrin-like domain, thrombospondin type-1 repeat, cysteine-rich domain, spacer region, and additional thrombospondin repeats. This recombinant is produced in HEK293 cells, an expression system that supports the glycosylation and disulfide-bond formation required for proper folding and secretory pathway processing of this class of enzyme. ADAMTS-14 displays aminoprocollagen type I N-proteinase activity, processing the N-propeptide of fibrillar collagen in a manner that partially overlaps with the related enzyme ADAMTS-2, and is synthesised as a latent zymogen requiring activation. It additionally cleaves lysyl oxidase (LOX) at a site downstream of the LOX propeptide cleavage site, generating a distinct short LOX isoform. For in-vitro research, the recombinant protein is suited to direct substrate cleavage assays using procollagen type I or LOX as substrates, as well as fluorogenic peptide-based activity measurements. It serves as a positive control antigen for antibody validation workflows; researchers using this recombinant for that purpose can pair it with the matched Triple Point Biologics antibody (SKU: RP-ADAMTS14), which has been validated for Western blot. The defined recombinant source provides a consistent, characterised standard for inhibitor IC50 determinations and binding studies.

Background

ADAMTS-14 is a member of a 19-protease family that collectively regulate extracellular matrix assembly, remodelling, and signalling. Within this family, ADAMTS-14 belongs to the procollagen N-proteinase subgroup alongside ADAMTS-2 and ADAMTS-3. Its principal characterised activity is cleavage of the N-propeptide of fibrillar procollagens — predominantly type I — a step necessary for proper collagen fibril diameter regulation and tensile matrix assembly. Published work has also established that ADAMTS-14 cleaves lysyl oxidase downstream of its propeptide site (PubMed: 31152061), implicating it in the post-translational processing cascade that ultimately governs collagen crosslinking and matrix stiffness. In musculoskeletal research, ADAMTS-14 has been investigated in the context of connective tissue integrity. A published association study examined the ADAMTS14/rs4747096 single-nucleotide polymorphism in relation to knee osteoarthritis risk factors (Elshaarawy et al., 2024, BMC Musculoskelet Disord), reflecting broader interest in how genetic variation in ECM remodelling enzymes influences joint disease susceptibility — a line of inquiry in which recombinant ADAMTS-14 protein can serve as a biochemical reference point. Beyond the ECM field, ADAMTS14 expression has been characterised as a research target in oncology contexts. In colorectal cancer, the transcription factor ONECUT2 has been reported to activate ADAMTS14 expression and promote cancer stemness via the Wnt signalling pathway (Jiang Y, 2025, Hum Cell). Separately, IL-6-driven regulation of ADAMTS14 through MAPK and PI3K signalling has been described in colorectal cancer models (Hacioglu N et al., 2026, J Cell Commun Signal). Genetic polymorphisms in ADAMTS14 have additionally been evaluated for associations with gastric cancer susceptibility and prognosis in a Chinese Han cohort (Li P et al., 2025, Gastric Cancer). These published studies collectively establish ADAMTS14 as a gene whose expression is responsive to inflammatory and oncogenic signalling, making the recombinant protein useful for antibody validation in tumour tissue sections and for functional experiments designed to interrogate its catalytic contributions in disease-relevant cell-based models. ADAMTS-14 localises to the extracellular space and matrix following secretion, and its activity is regulated at the level of zymogen activation — a property relevant to researchers designing activation protocols for in-vitro assay systems. Triple Point Biologics has been producing proteinase and inhibitor antibodies since 1994, and the matched antibody (RP-ADAMTS14) provides a validated companion reagent for Western blot and IHC experiments where this recombinant serves as the positive-control standard.

Applications

  • Procollagen type I N-propeptide cleavage activity assay
  • Lysyl oxidase (LOX) substrate cleavage and processing assay
  • Fluorogenic peptide substrate-based metalloproteinase activity measurement
  • Inhibitor IC50 determination against ADAMTS-14 catalytic activity
  • Positive control antigen for Western blot validation (pair with RP-ADAMTS14)
  • IHC positive-control tissue standard for anti-ADAMTS14 antibody (RP-ADAMTS14) optimisation
  • Zymogen activation kinetics and propeptide processing studies
  • Pull-down and binding assays to identify novel extracellular matrix interaction partners

References

  1. Hacioglu N et al. Inflammatory cytokine IL-6 regulates ADAMTS14 expression through MAPK and PI3K signaling in colorectal cancer. J Cell Commun Signal. 2026. doi: 10.1002/ccs3.70092. PMID: 42325598.
  2. Jiang Y. ONECUT2-driven activation of ADAMTS14 boosts colorectal cancer stemness via Wnt pathway. Hum Cell. 2025. doi: 10.1007/s13577-025-01319-3. PMID: 41225269.
  3. Li P et al. The impact of ADAMTS14 genetic polymorphisms and its function on susceptibility to and prognosis of gastric cancer in a Chinese Han population. Gastric Cancer. 2025. doi: 10.1007/s10120-025-01598-7. PMID: 39992602.
  4. Elshaarawy GA et al. The association between ADAMTS14/rs4747096 gene polymorphism and some risk factors and knee osteoarthritis. BMC Musculoskelet Disord. 2024. doi: 10.1186/s12891-024-07943-8. PMID: 39472918.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant ADAMTS-14 on SDS-PAGE or Western blot?

The full-length human ADAMTS-14 sequence (UniProt Q8WXS8) encodes 1,223 amino acids, giving a calculated polypeptide mass of ~135 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation adds appreciable mass; expect a diffuse band running at approximately 150–170 kDa under reducing SDS-PAGE conditions. The smearing is characteristic of the multiple glycosylation sites in the TSP repeats and spacer region. If you are blotting with RP-ADAMTS14, this is the band range to gate on for a clean positive control.

Is this recombinant ADAMTS-14 the mature active form or the full-length zymogen?

ADAMTS-14 is naturally synthesised as a latent zymogen with a prodomain that must be removed for catalytic activity. This recombinant is supplied as the active enzyme — the prodomain has been processed during HEK293 secretory pathway handling and/or post-purification activation, yielding a form with exposed catalytic zinc-binding site. The prodomain removal also slightly reduces the apparent SDS-PAGE band compared to unprocessed precursor. Lot-specific activation data are available on the CoA; if your assay requires confirmed zymogen as a baseline control, note that this product is not suitable for that use case.

What substrates can I use to measure ADAMTS-14 N-proteinase activity in a fluorescent assay?

ADAMTS-14 displays procollagen type I N-proteinase (pNPI) activity, cleaving the N-propeptide of fibrillar procollagens at the same scissile bond targeted by ADAMTS-2. For a fluorescent activity assay, a FRET-peptide spanning the ADAMTS-2/14 consensus cleavage site in the pro-α1(I) chain (e.g., Mca-EALQGPQTFGER↓GQAQP-Lys(Dnp)) is the most widely validated substrate. Alternatively, the general metalloproteinase substrate Mca-KPLGL↓DPAKG-Lys(Dnp) can confirm bulk metalloproteinase activity but lacks specificity. For quantitative kinetic work, start with 10–50 µM peptide substrate.

What buffer conditions should I use for ADAMTS-14 activity assays, and is the storage buffer compatible?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ — is formulated to maintain metalloproteinase stability and can be used directly in activity assays at low dilution. For optimal catalytic throughput, dilute into a working assay buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5–10 mM CaCl₂, 0.05% Brij-35. The calcium is essential for active site integrity; do not substitute with EDTA-containing buffers. Avoid reducing agents such as DTT above 1 mM, which can disrupt the disulfide-stabilised ancillary domains.

What starting concentration of recombinant ADAMTS-14 should I use for an enzyme activity assay?

A working starting point for fluorescent FRET-peptide assays is 1–10 nM recombinant ADAMTS-14 in a 100 µL reaction volume. At this range, initial velocity is linear with enzyme concentration for most peptide substrates at 10–50 µM. For native procollagen substrate assays, titrate upward to 5–50 nM, as the macromolecular substrate has a substantially lower kcat/KM than short peptides. Run a no-enzyme blank and a no-substrate blank in parallel. If inhibitor IC₅₀ determinations are planned, use the lowest enzyme concentration that gives a reliable signal-to-noise ratio (≥5:1 above background).

Can I use recombinant ADAMTS-14 as a positive control for Western blot with the RP-ADAMTS14 antibody?

Yes — this is the primary validated use case for pairing REC-ADAMTS14 with RP-ADAMTS14. The rabbit polyclonal antibody (RP-ADAMTS14) was raised and validated in the same laboratory that produced this recombinant, so epitope recognition against the HEK293-expressed glycoform is confirmed. Load 20–50 ng of REC-ADAMTS14 per lane alongside your cell lysate samples. Expect a band at ~150–170 kDa under reducing conditions. This setup also serves as a molecular weight reference and antibody titration anchor when optimising RP-ADAMTS14 for new cell/tissue lysate matrices.

How much recombinant ADAMTS-14 should I load for a Western blot positive control lane?

For a standard chemiluminescent Western blot using RP-ADAMTS14, load 20–50 ng of REC-ADAMTS14 per lane on a 4–12% Bis-Tris gradient gel. At 20 ng, a clean single band at ~150–170 kDa is detectable with RP-ADAMTS14 at 1:1,000–1:2,000 dilution and an HRP-conjugated anti-rabbit secondary at 1:5,000. If your cell lysate lanes contain low endogenous ADAMTS-14 (e.g., non-fibroblast lines), a 50 ng load provides a more visible reference band without saturating the signal. Dilute the recombinant in 1× SDS sample buffer immediately before loading; avoid repeated dilution-and-freeze cycles.

How should I store and handle recombinant ADAMTS-14 to preserve activity over multiple experiments?

Upon receipt, briefly centrifuge the vial, then aliquot into single-use volumes matching your typical assay requirement — 5–10 µL aliquots are practical for most labs. Store at -20°C; the 10% glycerol in the buffer provides cryoprotection for the metalloproteinase active site. Do not store at 4°C long-term: zinc metalloproteinases are susceptible to autolytic degradation and oxidative inactivation within days at refrigerator temperature. Avoid more than one freeze-thaw cycle per aliquot. Working stocks diluted in assay buffer should be used within 4 hours on ice. Shelf life is 12 months from date of receipt under recommended conditions.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS14 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →